Apricus Bio's Vitaros rejected in Switzerland due to 'quality issues'
This article was originally published in Scrip
Executive Summary
The Swiss medical agency Swissmedic has recommended against approval of San Diego-based Apricus Biosciences' erectile dysfunction product Vitaros (alprostadil) due to "quality related issues" issues with the drug's shelf life. This is in spite of the fact that the agency was happy with the company's data.